Shares of Pharvaris N.V. (NASDAQ: PHVS) tumbled 5.15% in intraday trading, as investors reacted to the company's disappointing first-quarter earnings report and mixed signals from analysts. The biopharmaceutical company, which focuses on developing novel therapies for hereditary angioedema (HAE), faced significant selling pressure following the release of its financial results.

Pharvaris reported a quarterly loss of $0.89 per share, missing the analyst consensus estimate of $0.82 by 8.54%. This represents a substantial increase in losses compared to the same period last year when the company reported a loss of $0.56 per share. The wider-than-expected loss appears to have shaken investor confidence, contributing to the stock's sharp decline.

Adding to the market uncertainty were conflicting reports about analyst price targets. While one report suggested that Wedbush raised its target price for Pharvaris from $25 to $27, another indicated that Wedbush had actually lowered its target to $17 while maintaining an Outperform rating. This discrepancy in analyst opinions may have further fueled investor skepticism, exacerbating the stock's downward movement. Despite the day's setback, the average analyst rating for Pharvaris remains a Buy, with a mean price target of $33.13, suggesting potential upside for long-term investors willing to weather the current volatility.